Fibrinogen

Mechanism :

Fibrinogen (coagulation factor I), a protein found in normal plasma, is required to clot blood.

Indication :

Congenital fibrinogen deficiency

Contraindications :

Severe, immediate hypersensitivity reactions, including anaphylaxis to fibrinogen, human plasma-derived products, or any component of the formulation.

Dosing :

Maintain a target fibrinogen level of 100 mg/dL for minor bleeding and 150 mg/dL for major bleeding.

When baseline fibrinogen level is known:

Fibryga Dose (mg/kg) = [Target level (Mg/dL) - measured level (Mg/dL)] divided by 1.8 (Mg/dL per mg/kg body weight)

RiaSTAP Dose (mg/kg) = [Target level (Mg/dL) - measured level (Mg/dL)] divided by 1.7 (Mg/dL per mg/kg body weight)

When baseline fibrinogen level is not known:

70 mg/kg IV.

Adverse Effect :

Headache, erythema, pruritus, vomiting, weakness, fever.

Interaction :

No known significant interactions.

Hepatic Dose :

In patients with hepatic impairment, the potential benefit of treatment with human plasma fibrinogen should be weighed against the risk of thromboembolic complications. Use with caution and do close monitoring.